Perfluorocarbons in Ophthalmology
INTRODUCTION Perfluorocarbon liquids (PFCLs) were first developed in 1970s as possible substitutes to erythrocytes[1],[2] because of their capacity to dissolve relatively large amounts of oxygen. Initial trials with these compounds focused on their feasibility to be used as blood substitutes. These experiments proved the biocompatibility of these compounds. Based on their properties, they were then introduced for intraocular use, in what has become a milestone in vitreoretinal surgery. After animal studies confirmed the safety of PFCL compounds as vitreous substitutes, Chang et al in 1987 first described the successful intraocular use of low viscosity liquid fluorocarbons (perfluorotributylamine and perfluorodecalin) in four patients with complicated retinal detachments.[3],[4] Long-term tamponade in animal models demonstrated retinal atrophy and retinal necrosis at the perfluorocarbon aqueous interface after 4 weeks even when highly purified PFCL compounds (perfluorodecalin) were used

